CTIS2022-502839-19-00进行中（未招募）1 期
J2A-MC-GZGP A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral LY3502970 Compared With Placebo in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1) - J2A-MC-GZGP
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 3,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Have obesity or overweight, If overweight, must also have one of the following: High blood pressure, high cholesterol, obstructive sleep apnea or heart disease., Have at least 1 self-report of an unsuccessful at dietary effort to lose weight
排除标准
- •Have Type 1 diabetes, Type 2 diabetes, or any other types of diabetes, history of ketoacidosis, or hyperosmolar state/coma, Have a self-reported change in body weight >5 kg (11 pounds) within 90 days prior to screening., Have family (first-degree relative) or personal history of MTC or MEN2 syndrome, Have had a history of chronic or acute pancreatitis
研究者
相似试验
招募中
1 期
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor (ACHIEVE-5)Type 2 DiabetesCTIS2023-507280-18-00Eli Lilly & Co.520
进行中（未招募）
1 期
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight and Type 2 Diabetes (ATTAIN-2)Overweight, Obesity, Type 2 DiabetesCTIS2022-502837-24-00Eli Lilly & Co.1,460
招募中
1 期
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3)Cardiovascular Disease, ObesityCTIS2023-503659-88-00Eli Lilly & Co.1,800
招募中
1 期
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-OUTCOMES)CTIS2023-508630-34-00Eli Lilly & Co.10,000
进行中（未招募）
1 期
A Study to Evaluate Further Therapeutic Strategies with Guselkumab in Patients with Moderate-to-Severe Plaque-Type PsoriasisModerate to Severe Plaque Type PsoriasisMedDRA version: 20.0 Level: PT Classification code 10037153 Term: Psoriasis System Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2018-001238-16-FRJanssen-Cilag International N.V.950